What are the guidelines for Sexually Transmitted Infections (STIs) testing and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

STI Testing Guidelines

All sexually active individuals should receive regular STI screening based on their risk factors, with annual testing recommended at minimum for those who are sexually active and more frequent testing (every 3-6 months) for high-risk populations. 1

General STI Screening Recommendations

Who Should Be Tested

  • All sexually active individuals should receive appropriate STI screening
  • Higher risk populations requiring more frequent testing:
    • Men who have sex with men (MSM)
    • Individuals with multiple partners
    • Persons who exchange sex for drugs
    • Individuals with a history of STIs
    • Sexual partners of persons with STIs

Testing Frequency

  • Standard recommendation: Annual testing for sexually active individuals
  • High-risk individuals: Testing every 3-6 months 1
  • MSM: Biannual screening has been shown to avert up to 72% of gonorrhea and 78% of chlamydia infections compared to current recommendations 2

Recommended STI Tests

Blood Tests

  • HIV: Testing should be offered to all sexually active individuals, especially those with risk factors 1
  • Syphilis: Serologic testing using Rapid Plasma Reagin (RPR) or similar test, with confirmatory testing if positive 1
  • Hepatitis B: Testing for hepatitis B surface antigen (HBsAg) 1

Site-Specific Testing

  • Gonorrhea and Chlamydia:
    • Nucleic acid amplification tests (NAATs) from appropriate sites of potential exposure (genital, rectal, pharyngeal) 3
    • NAATs have high sensitivities (86.1%-100%) and specificities (97.1%-100%) 4
  • Trichomoniasis: NAATs from urine or vaginal specimens 3

Special Populations

Pregnant Women

Pregnant women should receive comprehensive screening including:

  • Syphilis testing at first prenatal visit (repeat in third trimester for high-risk women)
  • Hepatitis B surface antigen testing
  • HIV testing
  • Gonorrhea testing for women at risk or in high-prevalence areas
  • Chlamydia testing for women under 25 or with new/multiple partners 3

Men Who Have Sex With Men (MSM)

  • Annual testing is suboptimal - only one-third report regular testing despite high risk behaviors 5
  • Asymptomatic STIs are common (19.9% prevalence in one study of HIV-positive MSM) 6
  • Screening should include extragenital sites (pharyngeal, rectal) as 53-100% of extragenital gonorrhea and chlamydia infections are asymptomatic 4

Sexual Assault Survivors

Initial examination should include:

  • NAATs for chlamydia and gonorrhea
  • Testing for trichomoniasis
  • Serum samples for HIV, hepatitis B, and syphilis 3

Treatment Considerations

For common STIs, standard treatments include:

  • Gonorrhea: Ceftriaxone 250mg IM single dose 3
  • Chlamydia: Azithromycin 1g orally single dose or doxycycline 100mg twice daily for 7 days 7, 8
  • Syphilis: Penicillin (doxycycline 100mg twice daily for 2 weeks for early syphilis in penicillin-allergic patients) 7
  • Trichomoniasis: Metronidazole 2g orally in single dose 3

Common Pitfalls to Avoid

  1. Inadequate site sampling: Failing to test all potential exposure sites (oral, rectal, genital) can miss infections
  2. Relying on symptom-driven testing: 70% of HSV and trichomoniasis infections and up to 100% of extragenital gonorrhea/chlamydia are asymptomatic 4
  3. Insufficient testing frequency: Annual testing may be inadequate for high-risk populations
  4. Overlooking partner notification: Partner notification is essential for preventing reinfection and ongoing transmission 3
  5. Ignoring antimicrobial resistance: Resistance limits oral treatment options for gonorrhea and M. genitalium 4

Reporting Requirements

  • Syphilis, gonorrhea, and AIDS are reportable in every state
  • Chlamydia is reportable in most states
  • Clinicians should be familiar with local reporting requirements
  • Reports are maintained in strict confidentiality and in most jurisdictions are protected by statute from subpoena 3

Regular STI screening is crucial for early detection and treatment, which can significantly reduce transmission rates and prevent long-term complications such as infertility, increased HIV risk, and other serious health outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.